Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Change in Cash (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Change in Cash for 6 consecutive years, with -$63.4 million as the latest value for Q4 2025.

  • Quarterly Change in Cash fell 1046.18% to -$63.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$45.5 million through Dec 2025, down 17.8% year-over-year, with the annual reading at -$45.5 million for FY2025, 17.8% down from the prior year.
  • Change in Cash hit -$63.4 million in Q4 2025 for Lyell Immunopharma, down from $24.8 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $320.1 million in Q2 2021 to a low of -$170.9 million in Q3 2021.
  • Historically, Change in Cash has averaged -$4.0 million across 5 years, with a median of -$15.5 million in 2022.
  • Biggest YoY gain for Change in Cash was 781.89% in 2023; the steepest drop was 2040.45% in 2023.
  • Year by year, Change in Cash stood at -$99.7 million in 2021, then soared by 107.27% to $7.2 million in 2022, then tumbled by 2040.45% to -$140.6 million in 2023, then skyrocketed by 104.77% to $6.7 million in 2024, then tumbled by 1046.18% to -$63.4 million in 2025.
  • Business Quant data shows Change in Cash for LYEL at -$63.4 million in Q4 2025, $24.8 million in Q3 2025, and -$21.6 million in Q2 2025.